Viral Hypothesis and Antiviral Treatment in Alzheimer’s Disease
Purpose of Review
Viruses, particularly herpes simplex virus (HSV), may be a cause of Alzheimer’s disease (AD). The evidence supporting the viral hypothesis suggests that antiviral treatment trials, which have not been conducted, are warranted.
HSV1 (oral herpes) and HSV2 (genital herpes) can trigger amyloid aggregation, and their DNA is common in amyloid plaques. HSV1 reactivation is associated with tau hyperphosphorylation and possibly tau propagation. Anti-HSV drugs reduce Aβ and p-tau accumulation in infected mouse brains. Clinically, after the initial oral infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and recurrent reactivation may produce neuronal damage and AD pathology. Clinical studies show cognitive impairment in HSV seropositive patients, and antiviral drugs show strong efficacy against HSV.
An antiviral treatment trial in AD is clearly warranted. A phase II treatment trial with valacyclovir, an anti-HSV drug, recently began with evaluation of clinical and biomarker outcomes.
KeywordsAlzheimer’s disease Viral hypothesis Dementia Amyloid Tau Antiviral treatment
Compliance with Ethical Standards
Conflict of Interest
Davangere P. Devanand reports grants from the National Institute of Aging and Avanir and personal fees from Acadia, Eisai, Genetech, and Axovant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.•• Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, et al. Microbes and Alzheimer’s disease. J Alzheimers Dis. 2016;51(4):979–84. The review by Itzhaki and colleagues is a consensus statement by 31 leading experts in the field demonstrating the high likelihood of an infectious etiology for Alzheimer’s disease with herpes simplex virus being the most likely culprit. PubMedPubMedCentralGoogle Scholar
- 13.Liedtke W, Opalka B, Zimmermann CW, Lignitz E. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. J Neurol Sci 1993;116(1):6–11.Google Scholar
- 15.Mori I, Nishiyama Y, Yokochi T, Kimura Y. Olfactory transmission of neurotropic viruses. J Neuro-Oncol. 2005;11(2):129–37.Google Scholar
- 19.Chattopadhyay K, Williamson AL, Hazra A, Dandara C. The combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC Cancer. 2015;15(1):680.PubMedPubMedCentralGoogle Scholar
- 21.D’Aiuto L, Prasad KM, Upton CH, Viggiano L, Milosevic J, Raimondi G, et al. Persistent infection by HSV-1 is associated with changes in functional architecture of iPSC-derived neurons and brain activation patterns underlying working memory performance. Schizophr Bull. 2014;41(1):123–32.PubMedPubMedCentralGoogle Scholar
- 25.Cummings JL, Zhong K. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Rev of Clin Pharmacol. 2014;7(2):161–5.Google Scholar
- 28.• Lövheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F. Herpes simplex infection and the risk of Alzheimer’s disease: a nested case-control study. Alzheimer's Dement. 2015;11(6):587–92. The two papers by Lovheim et al describe the results of epidemiological studies that show an association between herpes simplex virus infection and Alzheimer’s disease. Google Scholar
- 29.• Lövheim H, Gilthorpe J, Adolfsson R, Nilsson LG, Elgh F. Reactivated herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimer's Dement. 2015;11(6):593–9. The two papers by Lovheim et al describe the results of epidemiological studies that show an association between herpes simplex virus infection and Alzheimer’s disease. Google Scholar
- 30.GlaxoSmithKline. Valtrex®. Research Triangle Park, NC. 2011.Google Scholar
- 44.Kobayashi N, Nagata T, Shinagawa S, Oka N, Shimada K, Shimizu A, et al. Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer’s disease. Biochem Biophys Res Commun. 2013;430(3):907–11.PubMedGoogle Scholar
- 45.Mancuso R, Baglio F, Agostini S, Agostini MC, Laganà MM, Hernis A, et al. Relationship between herpes simplex virus-1-specific antibody titers and cortical brain damage in Alzheimer’s disease and amnestic mild cognitive impairment. Front Aging Neurosci. 2014 Oct 15;6:285.PubMedPubMedCentralGoogle Scholar
- 47.Dickerson F, Stallings C, Sullens A, Origoni A, Leister F, Krivogorsky B, et al. Association between cognitive functioning, exposure to herpes simplex virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. Brain Behav Immun. 2008;22(7):1103–7.PubMedGoogle Scholar
- 63.Hodge RA, Field HJ. Antiviral agents for herpes simplex virus. Adv Pharmacol. 2013;67(1):1–38.Google Scholar
- 68.Lycke J, Malmeström C, Ståhle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. J Antimicrob Chemother. 2003;47(8):2438–41.Google Scholar
- 70.Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 2010;54(3):1146–51.PubMedGoogle Scholar
- 73.Lycke J, Andersen O, Svennerholm B, Appelgren L, Dahlöf C. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. Journal of Antimicrob Chemother. 1989;24(6):947–54.Google Scholar